CStone's sugemalimab shows strong long-term lung cancer survival
CStone Pharmaceuticals (HKEX:2616) announced the publication of long-term survival data from its Phase III GEMSTONE-302 trial in The Lancet Oncology, demonstrating significant benefits of sugemalimab in treating metastatic non-small cell lung cancer (NSCLC). The study revealed a 4-year overall survival (OS) rate of 32.1% for patients receiving sugemalimab combined with platinum-based chemotherapy, nearly double the 17.3% rate observed with chemotherapy alone. Notably, patients with baseline brain metastases showed a 4-year survival rate of 36.4% with sugemalimab. Sugemalimab is approved in China, the EU, and the UK as a first-line treatment for metastatic NSCLC, and CStone aims to expand its global reach through commercialization partnerships.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when CStone Pharmaceuticals publishes news
Free account required • Unsubscribe anytime